应用组织微阵列技术探讨卵巢上皮性肿瘤P-gp、GST-π、TOPOⅡ的表达及意义

The expression of p-glycoprotein,glutathione s-transferase and topoismarase Ⅱ in ovarian carcinoma

目的探讨P-糖蛋白(P-gp)、谷胱苷肽S转移酶(GST-π)、拓扑异构酶Ⅱ(TOPOⅡ) 在卵巢上皮性肿瘤中的表达及意义。方法应用组织微阵列技术和免疫组织化学Elivision法,检测 104例卵巢上皮性肿瘤组织中P-gp、GST-π、TOPOⅡ的耐药性表达。结果在59例卵巢癌中,P-gp、 GST-π、TOPOⅡ的耐药性表达率分别为61．02％(36／59)、49．15％(29／59)、72．88％(43／59);P-gp与 GST-π、P-gp与TOPOⅡ、GST-π与TOPOⅡ及P-gp、GST-π与TOPOⅡ的耐药共表达阳性率分别为 40．67％(24／59)、37．28％(22／59)、32．20％(19／59)、25．42％(15／59);绝经后卵巢癌GST-π的耐药表达(60．52％)高于绝经前患者(33．33％,P=0．045);分化高(G1～G2)卵巢癌TOPOⅡ的耐药表达 (80．85％)高于分化低者(G3)(50．00％,P=0．028);病情进展组P-gp耐药表达明显高于无进展组(P =0．027);P-gp、GST-π、TOPOⅡ的耐药性表达与卵巢癌组织类型、手术病理分期、腹水细胞学及有无淋巴结转移无关。结论应用免疫组织化学方法联合检测卵巢癌中P-gp、GST-π、TOPOⅡ的耐药性表达,对于临床化疗敏感性的预测有一定提示,对预后的判断可能提供有价值的参考。

Objective To detect the resistant expression of p-glycoprotein（P-gp）, glutathione stransferase（GST-π）, topoismarase Ⅱ （TOPO Ⅱ ） and significances in ovarian carcinoma. Methods High-throughput tissue microarray technique and Elivision immunohistochemical technique were used to investigate resistant expression of P-gp, GST-π and TOPO Ⅱ in 104 cases of ovarian carcinoma. Results In 59 cases, the expression frequency of P-gp, GST-π and TOPO Ⅱ was 61. 02% （36/59）, 49. 15%（29/59） and 72. 88%（43/59）, respectively. The coexpression rate of P-gp and GST-π, P-gp and TOPO Ⅱ, GST-π and TOPO Ⅱ, P-gp, GST-π and TOPO Ⅱ was 40. 67%（24/59）, 37. 28% （22/59）, 32. 20%（19/59）, 25. 42%（15/59）, respectively. The resistant expression of GST-π was higher（60. 52%） in ovarian carcinoma from patents after menopause compared with those before undergoing menopause. The expression of TOPO Ⅱ was higher（80. 85%） in ovarian carcinoma from the high-metastatic（G1-G2） than the low-metastatic（G3）. Conclusion The resistant expression of P-gp, GST-π and TOPO Ⅱ were used to predict the sensitivity of chemotherapy and reference for predicting the prognosis.